When we think of the large molecules of significance to immunology, we focus on proteins: antibodies, T-cell receptors, cytokines, interferons. Proteins come from genes, and human genome research has made sequencing almost free. We are in the midst of an epochal shift, which will result in DNA becoming the central molecule in immunological innovation. That’s ImmunoGenomics. That’s us.
The company has an extensive internal R&D program. Contact us if you’d like to collaborate.
When cells in living tissue die, their contents are shed into the bloodstream where they circulate until digested and reabsorbed or excreted; amongst these released contents are fragments of genomic DNA. In the case of organ transplant recipients, cells from the donated organ will have a different genome than other cells from the recipient. We have developed methods to identify donor DNA by sequencing from a blood sample, letting us monitor the state of the transplanted organ and detect early signs of immune activation against the donated organ. With published results that show earlier detection of rejection than biopsy in heart transplant recipients, this technology promises to transform post-transplant management.
ImmuMetrix has developed state-of-the-art assays for Immune Repertoire Profiling, that is, sequencing the immune repertoire and bioinformatics for analyzing and interpreting it. With applications in cancer, transplantation, autoimmunity, vaccines, allergies and asthma (asthma is a type of allergy), our internal R&D is focused on the most important of these. Contact us if you’d like to collaborate.